Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Allison Berger"'
Autor:
Evan F. Lind, Vi Lam, Nathan D. Pennock, Scott R Best, Adam Kittai, Alexey V. Danilov, Nur Bruss, Allison Berger, Susan E. Murray, Tingting Liu, Olga V. Danilova
Publikováno v:
Leukemia
Novel targeted agents used in therapy of lymphoid malignancies, such as inhibitors of B-cell receptor-associated kinases, are recognized to have complex immune-mediated effects. NEDD8-activating enzyme (NAE) has been identified as a tractable target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcae410fe576a9e2b7a646012b4569dc
https://europepmc.org/articles/PMC8288064/
https://europepmc.org/articles/PMC8288064/
Autor:
Neil MacLean, Shawn Brennan, Adam C. Smith, Rose Hurren, Allison Berger, Xiaoming Wang, Razq Hakem, Marcela Gronda, Mark D. Minden, Sara Farshchi Zarabi, Simon Kavanagh, Tary Traore, G. Wei Xu, Aaron D. Schimmer, Emil F. Pai, Samir H. Barghout, Ondrej Halgas, Michael Milhollen, Marc L. Hyer, Parasvi S. Patel, Danny V. Jeyaraju
Publikováno v:
Leukemia. 33:37-51
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy for which new therapeutic approaches are required. One such potential therapeutic strategy is to target the ubiquitin-like modifier-activating enzyme 1 (UBA1), the initiating enzyme
Autor:
Craig Okada, Alexey V. Danilov, Nur Bruss, Allison Berger, Cody Paiva, Tingting Liu, Adam Kittai, Scott R Best, Taylor Hashiguchi
Publikováno v:
Blood advances. 3(1)
Alterations in the ubiquitin proteasome system (UPS) leave malignant cells in heightened cellular stress, making them susceptible to proteasome inhibition. However, given the limited efficacy of proteasome inhibitors in non-Hodgkin lymphoma (NHL), no
Autor:
Kathryn A. Rizzo, Steven Grant, Sri Lakshmi Chalasani, Lawrence F. Povirk, Liang Zhou, Yun Dai, Mohamed Rahmani, Allison Berger, Andrea Ferreira-Gonzalez, Lihong Li, Hui Lin, Catherine I. Dumur, Yun Leng, Shuang Chen, Maciej Kmieciak, Yu Zhang
Publikováno v:
Blood. 127:2219-2230
Two classes of novel agents, NEDD8-activating enzyme (NAE) and histone deacetylase (HDAC) inhibitors, have shown single-agent activity in acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS). Here we examined mechanisms underlying interact
Autor:
Dennis Huszar, Allison Berger, Alejandro Gomez-Pinillos, Mi-Sook Kim, Amitkumar Mehta, Igor Proscurshim, Chirag Patel, Paolo Caimi, Bingxia Wang, Sarit Assouline, Sharon Friedlander
Publikováno v:
Blood. 134:1593-1593
Background TAK-981 is a first-in-class, small molecule inhibitor of SUMOylation, a reversible post-translational modification that regulates protein function by covalent attachment of small ubiquitin-like modifier (SUMO) proteins to a protein substra
Autor:
Isere Kuiatse, Hua Wang, Nibedita Chattopadhyay, Robert Z. Orlowski, Saurabh Menon, Judy Qiuju Shi, Junling Zhuang, Hans C. Lee, Vaishali Shinde, Allison Berger, Marc L. Hyer, Anna Kreshock, Stephen Tirrell, Sakeena Syed, Jie Yu, Richard J. Jones, Fazal Shirazi
Publikováno v:
Blood. 128:3296-3296
Background: The ubiquitin-proteasome system (UPS) has been validated as a target in multiple myeloma (MM) through the success of proteasome inhibitors such as bortezomib, but drug resistance is an emerging challenge. Targeting some of the upstream co